{
  "schema_version": 1,
  "generated_at": "2026-05-20T10:39:12Z",
  "ticker": "CRSP",
  "headlines": [
    {
      "title": "Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?",
      "publisher": "Zacks",
      "published_at": "2026-05-19T15:53:00+00:00",
      "age_hours": 18.770049033333333,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/intellias-pipeline-push-drive-long-155300020.html",
      "summary": "NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth."
    },
    {
      "title": "CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know",
      "publisher": "Zacks",
      "published_at": "2026-05-19T13:00:02+00:00",
      "age_hours": 21.65282681416667,
      "link": "https://finance.yahoo.com/markets/stocks/articles/crispr-therapeutics-ag-crsp-attracting-130002164.html",
      "summary": "Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store."
    },
    {
      "title": "CRISPR Therapeutics Enters Second Phase As CASGEVY Uptake And Data Build",
      "publisher": "Simply Wall St.",
      "published_at": "2026-05-18T06:11:16+00:00",
      "age_hours": 52.46560459388889,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/crispr-therapeutics-enters-second-phase-061116599.html",
      "summary": "CRISPR Therapeutics (NasdaqGM:CRSP) is entering a second phase of its business as the CASGEVY commercial rollout gains momentum. The company reports new patient initiations for CASGEVY alongside progress on reimbursement, including an agreement in Germany. Upcoming pipeline data and potential pediatric label expansion are expected to be important for future market uptake of CASGEVY. For investors tracking gene editing, CRISPR Therapeutics sits at the center of one of the most closely..."
    },
    {
      "title": "CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms",
      "publisher": "MarketBeat",
      "published_at": "2026-05-16T00:12:19+00:00",
      "age_hours": 106.44810459583333,
      "link": "https://www.marketbeat.com/instant-alerts/crispr-therapeutics-enters-second-phase-as-casgevy-momentum-builds-pipeline-data-looms-2026-05-15/?utm_source=yahoofinance&utm_medium=yahoofinance",
      "summary": "CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a \u201csecond phase\u201d as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host"
    },
    {
      "title": "1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?",
      "publisher": "Motley Fool",
      "published_at": "2026-05-11T20:35:00+00:00",
      "age_hours": 206.07004904222222,
      "link": "https://www.fool.com/investing/2026/05/11/1-top-wall-street-analyst-thinks-crispr-therapeuti/",
      "summary": "The biotech's innovative platform could pay off."
    }
  ]
}